[Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
Following various articles in literature which have appeared in the last 3 years regarding the neurotoxicity of desferrioxamine B we studied, from the auditory functionality point of view, 95 patients affected with transfusion-dependent thalassemic syndromes, under regular chelation treatment with desferrioxamine B. Our results lead us to conclude that at standard doses, between 40 and 60 mg/Kg/day, desferrioxamine B does not demonstrate a neurotoxicity enough to cause an organic deficit in the auditory sphere, while maintaining therapeutic efficacy.
Gaini
R M
RM
II Clinica Otorinolaringoiatrica, Università di Milano, Italia.
Moretti
E
E
Boffa
C
C
Terzoli
S
S
Carnelli
V
V
D000158:Acoustic Impedance Tests; D000293:Adolescent; D000328:Adult; D001299:Audiometry; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D013789:Thalassemia / Q000188:drug therapy* / Q000503:physiopathology
D003676:Deferoxamine
Valutazione audiologica in pazienti affetti da sindromi talassemiche trattati con desferossamina B.